How does glucagon raise blood sugar?

It signals the liver, through the glucagon receptor, to break down stored glycogen and make new glucose, which raises blood glucose within minutes.

Do I still need to do anything after a glucagon rescue?

Yes. Once the person can swallow safely they should eat carbohydrate to restore glycogen stores, and emergency medical help should be sought, especially if there is no response.

When might glucagon not work?

It can be ineffective when the liver's glycogen is depleted, such as after prolonged fasting, in adrenal insufficiency, in chronic hypoglycemia, or with heavy alcohol use.

Is glucagon a bodybuilding or fat-loss peptide?

No. It is an emergency and diagnostic medicine; using it outside its approved medical purpose is unsafe and not supported by evidence.

EMA-approvedaka GlucaGen, Baqsimi, Gvoke

Glucagon — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Glucagon (also known as GlucaGen) is a peptide catalogued under Hormones & Metabolic (Pancreatic hormone). It is described as: Glucagon receptor. Documented context: Severe hypoglycemia. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Glucagon?

Glucagon is the pancreatic alpha-cell peptide hormone and an FDA- and EMA-approved medicine used to treat severe hypoglycemia, available as injectable kits, a ready-to-use pen, an intranasal powder, and a stable analog (dasiglucagon).

It is also used as a diagnostic aid to relax the gut during imaging and endoscopy.

Evidence for its hypoglycemia indication is strong and human-based, including multiple randomized controlled trials of nasal and analog formulations.

How does Glucagon work?

Glucagon binds the hepatic glucagon receptor, a Gs-coupled GPCR, raising cAMP to stimulate glycogenolysis and gluconeogenesis and thereby increase blood glucose.

Its glucose-raising effect depends on adequate hepatic glycogen stores, so it works poorly in fasted, glycogen-depleted, or alcohol-affected states.

What does the research say about Glucagon?

Intranasal glucagon reversed insulin-induced hypoglycemia about as effectively as intramuscular glucagon in adults with type 1 diabetes, meeting non-inferiority for glucose recovery. ^[1]
In youth with type 1 diabetes, needle-free nasal glucagon powder raised plasma glucose comparably to intramuscular glucagon. ^[2]
The next-generation analog dasiglucagon produced rapid, reliable plasma-glucose recovery in a phase 3 severe-hypoglycemia trial. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study — Rickels MR et al., Diabetes Care 2016. (Randomized controlled crossover trial)
[2] Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes — Sherr JL et al., Diabetes Care 2016. (Randomized controlled trial (pediatric))
[3] Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial — Pieber TR et al., Diabetes Care 2021. (Phase 3 randomized double-blind RCT)
[4] Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog — Hovelmann U et al., Diabetes Care 2018. (Randomized controlled pharmacology trial)
[5] The New Biology and Pharmacology of Glucagon — Muller TD et al., Physiological Reviews 2017. (Narrative review)
[6] Dasiglucagon: First Approval — Blair HA et al., Drugs 2021. (Regulatory/drug review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Approved rescue products are given as fixed single doses by a caregiver during a severe hypoglycemic emergency (for example an intramuscular or subcutaneous injection, or one intranasal actuation), with a repeat and emergency call if there is no response.

This is context only and not a dosing instruction; actual product, dose, and administration must follow the specific label and a clinician's guidance.

Side effects & safety profile

The most common adverse effects are nausea and vomiting, and headache or nasal and upper-respiratory irritation with the nasal powder; serious hypersensitivity is rare.

Glucagon is contraindicated or cautioned in pheochromocytoma and insulinoma, and it may be ineffective when hepatic glycogen is depleted (prolonged fasting, adrenal insufficiency, chronic hypoglycemia, or alcohol use).

It is a rescue and diagnostic agent, not a chronic therapy; care after use still requires oral carbohydrate once the person can safely swallow, plus medical follow-up.

Stacking & combinations

Glucagon is used as an emergency counter-regulatory agent against insulin and is not intended to be combined with other peptides for performance or physique purposes.

Finding Glucagon vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is approved to treat severe hypoglycemia (low blood sugar) in people with diabetes and is also used as a diagnostic aid to relax the gastrointestinal tract during imaging or endoscopy.

References

[1] Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study — Rickels MR et al., Diabetes Care 2016. PMID: 26681725. View sourceStudy: Randomized controlled crossover trialNasal glucagon was non-inferior to intramuscular glucagon for reversing insulin-induced hypoglycemia in adults with type 1 diabetes.
[2] Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes — Sherr JL et al., Diabetes Care 2016. PMID: 26884472. View sourceStudy: Randomized controlled trial (pediatric)Nasal glucagon powder raised plasma glucose comparably to intramuscular glucagon in children and adolescents with type 1 diabetes.
[3] Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial — Pieber TR et al., Diabetes Care 2021. PMID: 35239971. View sourceStudy: Phase 3 randomized double-blind RCTReady-to-use dasiglucagon achieved rapid plasma-glucose recovery versus placebo in adults with type 1 diabetes and severe hypoglycemia.
[4] Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog — Hovelmann U et al., Diabetes Care 2018. PMID: 29273578. View sourceStudy: Randomized controlled pharmacology trialDasiglucagon showed a fast, dose-dependent glucose response supporting its use as a stable liquid rescue glucagon.
[5] The New Biology and Pharmacology of Glucagon — Muller TD et al., Physiological Reviews 2017. PMID: 28275047. View sourceStudy: Narrative reviewComprehensive review of glucagon receptor signaling, hepatic glucose regulation, and therapeutic applications.
[6] Dasiglucagon: First Approval — Blair HA et al., Drugs 2021. PMID: 34047955. View sourceStudy: Regulatory/drug reviewSummarizes the approval and clinical profile of dasiglucagon for severe hypoglycemia.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.